No Data
On November 22, livzon pharma (01513.HK) spent 8.42 million HKD to repurchase 0.321 million shares.
On November 22, Gelonghui reported that livzon pharma (01513.HK) announced the repurchase of 321,000 shares at a cost of 8.42 million HKD on November 22, 2024, with a repurchase price per share ranging from 26 to 26.5 HKD.
Livzon Pharmaceutical's Shares Under Business Partner Shareholder Plan Sold
Livzon Pharmaceutical Group Inc. (SZSE:000513) Stock Most Popular Amongst Public Companies Who Own 44%, While Individual Investors Hold 38%
Livzon Pharmaceutical Group Inc. (000513.SZ): The first phase of the medium and long-term business partner stock ownership plan has been completed.
On November 21, Glonghui announced that livzon pharmaceutical group inc. (000513.SZ) disclosed that as of November 20, 2024, a total of 2,348,960 shares of the company's stock held by the first phase of the long-term business partner holding plan have been completely sold through centralized auction trading, accounting for 0.25% of the company's total share capital. As of the date of this announcement, the assets of the current employee stock ownership plan are all in mmf. According to the provisions of the 'First Phase Holding Plan of the Long-term Business Partner Holdings Plan (Draft)', the current employee stock ownership plan has been fully implemented and will be terminated early, and the company will proceed according to this phase.
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings YetNo Data
No Data
